Shares of ResMed Inc. RMD rallied 1.61% to $237.13 Thursday, on what proved to be an all-around poor trading session for the ...

In a report released today, Mathieu Chevrier from Citi maintained a Hold rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs ...

Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

Goldman Sachs initiated coverage of ResMed (RMD) with a Buy rating and A$48.90 price target The firm says its Buy thesis is based on “robust” ...

The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...

Signal Advisors Wealth LLC increased its stake in ResMed Inc. (NYSE:RMD – Free Report) by 6.1% in the 4th quarter, according ...

Here's why brokers are feeling bullish about these three shares this week. The post Brokers name 3 ASX shares to buy today ...

Henry Schein, Inc. HSIC recently completed the acquisition of substantially all of the assets of Acentus, a national medical ...

Three Australian fund managers who delivered double-digit returns over the past 10 years share their views on what’s next for ...

Baird has upgraded DexCom (DXCM) to outperform, citing increasing confidence in the company's ability to return revenue ...

Edwards Lifesciences (EW) stock faces a downgrade at Wolfe due to concerns over its TAVR market prospects. Read more here.

All paying members at FNArena are being reminded they can set an email alert specifically for The Overnight Report. Go to ...